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Key points
† MH is rare, but its incidence
may be increasing.
† Prompt recognition is the key
to a safe outcome.
† These guidelines provide a
template for diagnosis and
treatment.
† Suspected cases and their
relatives should be followed
up and investigated for MH.
Survival from a malignant hyperthermia (MH) crisis is highly dependent on early recognition
and prompt action. MH crises are very rare and an increasing use of total i.v. anaesthesia is
likely to make it even rarer, leading to the potential risk of reduced awareness of MH. In
addition, dantrolene, the cornerstone of successful MH treatment, is unavailable in large
areas around the world thereby increasing the risk of MH fatalities in these areas. The
European Malignant Hyperthermia Group collected and reviewed all guidelines available
from the various MH centres in order to provide a consensus document. The guidelines
consist of two textboxes: Box 1 on recognizing MH and Box 2 on the treatment of an MH
crisis.
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The first known case of malignant hyperthermia (MH) sur-
vived because the anaesthetist quickly stopped anaesthesia
and surgery when he observed a set of strange clinical
signs. However, he was already alerted to a potential
problem because of a preoperative history of several
anaesthesia-related deaths in the patient’s family.1 The key
lesson learnt from this event is as relevant today as it was
back in 1960: survival from an MH crisis is highly dependent
on early recognition and prompt action.
MH crises are very rare and an increasing use of total i.v.
anaesthesia (TIVA) using non-triggering agents in many
Western European countries is likely to make it even rarer,
leading to the potential risk of reduced awareness of MH
among anaesthetists and theatre staff. However, recent
reports showed that the frequency of MH episodes has
increased, and due to the autosomal-dominant inheritance
in humans, prevalence of MH can be estimated up to 1:3000.2
In addition, dantrolene, the cornerstone of successful MH
treatment, is unavailable in many institutions in Eastern
European countries and in large areas around the world due
to its cost, thereby increasing the risk of MH fatalities in these
areas.
The European Malignant Hyperthermia Group (EMHG), a
leading international society working on MH, has therefore
decided to publish guidelines for the detection and handling
of an MH crisis. Many institutions have drawn up local guide-
lines and most countries with an MH Investigation Unit have
developed national guidelines. The EMHG Executive commit-
tee collected and reviewed all guidelines available from the
various MH centres in order to provide a consensus document.
It is hoped that this will be helpful, especially for countries
having no MH centre and therefore no national guidelines.
While recognizing that it is impossible to stipulate the
exact set-up for dealing with MH for each institution world-
wide, we are, nevertheless, convinced that the EMHG guide-
lines will provide a sound basis to help anaesthetists and
theatre staff in Europe and around the world ensure that
best practice is followed and enable them to plan ahead.
The guidelines consist of two textboxes: Box 1 on recog-
nizing MH and Box 2 on the treatment of an MH crisis.
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Box 1 EMHG Guidelines: Recognizing an MH crisis
Early recognition of an impending MH crisis and its immediate treatment is essential for the patient’s survival. As the clinical
signs associated with MH are not unique, anaesthetists must be able to recognize a pattern of signs in order to make a rapid
diagnosis.
Any patient may develop MH during or shortly after an anaesthetic where trigger agents are used—this can occur even in
patients who have had uneventful general anaesthesia previously.
Trigger agents are
† all volatile (inhalation) anaesthetic agents;
† succinylcholine.
Clinical signs
Early signs
Metabolic
† Inappropriately elevated CO2 production (raised end-tidal CO2 on capnography, tachypnoea if breathing spontaneously).
† Increased O2 consumption.
† Mixed metabolic and respiratory acidosis.
† Profuse sweating.
† Mottling of skin.
Cardiovascular
† Inappropriate tachycardia.
† Cardiac arrhythmias (especially ectopic ventricular beats and ventricular bigemini).
† Unstable arterial pressure.
Muscle
† Masseter spasm if succinylcholine has been used.
† Generalized muscle rigidity.
Later signs
† Hyperkalaemia.
† Rapid increase in core body temperature.
† Grossly elevated blood creatine phosphokinase levels.
† Grossly elevated blood myoglobin levels.
† Dark-coloured urine due to myoglobinuria.
† Severe cardiac arrhythmias and cardiac arrest.
† Disseminated intravascular coagulation.
Differential diagnosis
† Insufficient anaesthesia, analgesia, or both.
† Infection or septicaemia.
† Insufficient ventilation or fresh gas flow.
† Anaesthetic machine malfunction.
† Anaphylactic reaction.
† Phaeochromocytoma.
† Thyroid crisis.
† Cerebral ischaemia.
† Neuromuscular disorders.
† Elevated end-tidal CO2 due to laparoscopic surgery.
† Ecstasy or other dangerous recreational drugs.
† Malignant neuroleptic syndrome.
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Box 2 EMHG Guidelines: Managing an MH Crisis
Start treatment as soon as an MH crisis is suspected.
The clinical presentation of MH varies and treatment should be modified accordingly.
Treatment
Immediately
† Stop all trigger agents.
† Hyperventilate (use a minute volume 2–3 times normal) with 100% O2 at high flow.
† Declare an emergency and call for help.
† Change to non-trigger anaesthesia (TIVA).
† Inform the surgeon and ask for termination/postponement of surgery.
† Disconnect the vaporizer—do not waste time changing the circuit/anaesthetic machine.
Dantrolene
† Give dantrolene 2 mg kg21 i.v. (ampoules of 20 mg are mixed with 60 ml sterile water).
† Obtain dantrolene from other sources, for example, pharmacy/nearby hospitals—at least 36–50 ampoules may be
needed for an adult patient.
† Dantrolene infusions should be repeated until the cardiac and respiratory systems stabilize.
† The maximum dose (10 mg kg21) may need to be exceeded.
Monitoring
† Continue routine anaesthetic monitoring (SaO2, ECG, NIAP, E′CO2).
† Measure core temperature.
† Establish good i.v. lines with wide-bore cannulas.
† Consider inserting an arterial and central venous line, and a urinary catheter.
† Obtain samples for measurement of K+, CK, arterial blood gases, myoglobin, and glucose.
† Check renal and hepatic function and coagulation.
† Check for signs of compartment syndrome.
† Monitor the patient for a minimum of 24 h (ICU, HDU, or in a recovery unit).
Symptomatic treatment
Treat hyperthermia
† 2000–3000 ml of chilled (48C) 0.9% saline at i.v.
† Surface cooling: wet, cold sheets, fans, and ice packs placed in the axillae and groin.
† Other cooling devices if available.
† Stop cooling once temperature ,38.58C
Treat hyperkalaemia
† Dextrose: 50%, 50 ml with 50 IU insulin (adult dose).
† CaCl2: 0.1 mmol kg21 i.v. (e.g. 7 mmol¼10 ml for a 70 kg adult).
† Dialysis may be required.
Treat acidosis
† Hyperventilate to normocapnoea.
† Give sodium bicarbonate i.v. if pH, 7.2.
Treat arrhythmias
† Amiodarone: 300 mg for an adult (3 mg kg21 i.v.).
† b-blockers (e.g. propranolol/metoprolol/esmolol)—if tachycardia persists.
Maintain urinary output >2 ml kg21 h21
† Furosemide 0.5–1 mg kg21.
† Mannitol 1 g kg21.
† Fluids: crystalloids (e.g. lactated Ringer’s solution or 0.9% saline) i.v.
Consult your local Malignant Hyperthermia Investigation Unit about the case
Patients suspected of being MH-susceptible should undergo diagnostic testing using in vitro contracture testing (IVCT) at a
designated MH-laboratory (www.emhg.org).
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Action cards adapted for local conditions and resources
can be extremely helpful in dealing with an MH crisis. Such
a system, designed by the Australian and New Zealand MH
group (MHANZ),3 has proved to be a success in full-scale
simulation and can save valuable time.
It is important that once a case of MH is suspected, either
because of a full-blown MH crisis or a set of symptoms sug-
gestive of MH which resolved on stopping any trigger
agents, the patient and their relatives should always be
referred to a regional or national MH centre for further inves-
tigation wherever possible. The EMHG has previously pub-
lished guidelines for diagnosing MH susceptibility using the
IVCT test and genetic testing when indicated.4 5
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